Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.
Devita
D
Surjana
Gary M
GM
Halliday
Andrew J
AJ
Martin
Fergal J
FJ
Moloney
Diona L
DL
Damian
D000368:Aged; D000369:Aged, 80 and over; D002280:Basal Cell Carcinoma / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002471:Cell Transformation, Neoplastic; D016001:Confidence Intervals; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy* / Q000517:prevention & control; D016015:Logistic Models; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D016017:Odds Ratio; D016012:Poisson Distribution; D012878:Skin Neoplasms / Q000473:pathology*; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000627:therapeutic use*
D014803:Vitamin B Complex; D009536:Niacinamide